TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02502266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT01512992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home telehealth
Description: Patients receive tailored intervention according to their clinical complexity.~All patients in the intervention group receive:~* Personalised care plan~* Education on self-management~* Access to a personalized online health folder~* Access to Call center~* Access to primary care and hospital specialists; follow-up visits for evaluation of clinical recovery and care plan adjustments (if needed).~Patients with LOW complexity additionally receive:~* Daily videoconferences for the 1st week after discharge~* Remote monitoring for respiratory parameters. Sensors are selected on an individual basis by the medical specialists.~Patients with HIGH complexity additionally receive:~* Videoconferences for at least 1 month after discharge, scheduled on an individual basis.~* Remote monitoring for respiratory parameters.~* One monthly phone call from the call centre to promote and assess patient self-management.
Study: NCT03440489

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Six-minute walking test
Description: physical performance of the muscle measured by these tests

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 30 seconds chair stand test
Description: physical performance of the muscle measured by these tests
Study: NCT03937960

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate restricted group
Description: Prescribed low carbohydrate diet with set recipes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard low fat diet
Description: Diet with less than 20% total calorie intake from dietary fats
Study: NCT02675530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.~No drug administration for patients with schizophrenia
Study: NCT04501796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-Blind NT-I7
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double-Blind Placebo
Description: Placebo
Study: NCT00166530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
Study: NCT01351896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Polyvalent Vaccine
Description: Given IM (concurrently or sequentially)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Polyvalent Vaccine
Description: Given IM (concurrently or sequentially)
Study: NCT04501588

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Responsive training with no video feedback
Description: Parents will receive responsive training, but will not watch themselves on video to reflect on their strategy use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive training with no video feedback
Description: Parents will receive responsive training, but will not watch themselves on video to reflect on their strategy use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Responsive training with video feedback
Description: Parents will receive responsive training and watch themselves on video to reflect on their strategy use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive training with video feedback
Description: Parents will receive responsive training and watch themselves on video to reflect on their strategy use.
Study: NCT02374294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epiflo
Description: EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of \~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound.
Study: NCT02791308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus Cream 1% (Valeant)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus Cream, 1%
Study: NCT00111865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: The exercise group will perform supervised stationary cycle ergometer exercise 3 days/week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 80% of their VO2 reserve over the course of the intervention.
Study: NCT03612102

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Group Behavioral Treatment (IGBT)
Description: IGBT is a 5-day intensive treatment program, where cognitive behavioral therapy is provided to children and their parents delivered over 6-8 hours per day over the course of 5 days.
Study: NCT01164319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential PVI and subcutaneous cardiac monitor implantation
Description: The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.~The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
Study: NCT00271401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01164319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential PVI and subcutaneous cardiac monitor implantation
Description: The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.~The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential PVI and subcutaneous cardiac monitor implantation
Description: The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.~The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
Study: NCT02502266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT00966745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milrinone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04243772

Intervention type: OTHER
Intervention: Data extraction
Description: Data extraction from medical files
Study: NCT03757767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting for 26-hours
Description: All research subjects will have to fast for 26 hours in total.~All research subjects start with a standardized meal. Two hours after the standardized meal the samples in the fed state will be taken. Research participants are not allowed to eat anything after the consumption of the standardized meal until the second measurements on day 2, 26-hours later. There are 24 hours between the two measurement points.
Study: NCT03349476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MFAM
Description: Specifically, the mFAM Workstation accesses stored data of recorded electronic heart activity that has been obtained by conventional electrophysiological methods, using multi-electrode catheters placed in the heart (data inputs) for collection. Using proprietary software algorithms, the mFAM Workstation analyzes these data inputs and generates 3D anatomical structure.~mFAM improves on the FAM functionality by applying a model-based approach for reconstruction of left atrial chamber anatomy
Study: NCT01308099

Intervention type: DEVICE
Intervention: Blood Pressure and Blood Flow
Description: A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The probes also measure blood pressure. After 10 minutes, the arm blood pressure cuff will be inflated. The cuff will stay inflated for 5 minutes, then the air will be let out. A cuff will be place above the left calf and the left knee. The subject will lie quietly for 9 minutes, then blood pressure and calf blood flow will be measured for one minute. the lower leg cuff will be inflated after 1 minute, then the cuff will be deflated. The blood pressure and forearm blood flow will be recorded. Next, the cuff on the upper leg will be inflated for 5 minutes then, it will be released and the measurements of blood pressure and calf blood flow will be repeated.~The study lasts about 2 hours.
Study: NCT00096278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT00166530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 20 mg atorvastatin once daily for 12 weeks. Tablets
Study: NCT00096278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study: NCT02545244

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black Tea
Description: 0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
Study: NCT00096278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT02545244

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: 0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
Study: NCT03796364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard SRILI treatment
Description: Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard SRILI treatment
Description: Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
Study: NCT00798837

Intervention type: RADIATION
Group type: OTHER
Intervention: Intraprostatic maximal simultaneous boost
Description: Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~* The prescription dose will be 73.7 Gy in 28 fractions~* A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints.
Study: NCT02525744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (Humalog)
Description: Administered SC
Study: NCT02122042

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HBOT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBOT
Study: NCT01249794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non invasive ventilation
Description: continuous positive airways pressure
Study: NCT02875444

Intervention type: OTHER
Intervention: Angio-CT
Study: NCT02370953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VERION for toric IOL alignment
Description: The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, manual ink-marking for toric IOL alignment
Description: Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
Study: NCT04127513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammonium Lactate
Description: 12% ammonium lactate moisturizing cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urea
Description: 10% urea moisturizing cream
Study: NCT03213379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actimetry measures
Description: The patient will wear actigraphy bracelet during a week that will enable to record patients' movements. The report based on the recording will provide an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.The intervention consisted in 2 supplementary actimetry measures and sending of the actimetry reports to the investigator.
Study: NCT05146479

Intervention type: PROCEDURE
Intervention: Fluoride varnish and pit and fissure sealants onto first permanent molars
Description: Quarterly application of fluoride varnish. Application of pit and fissure sealant, and replacements if necessary.
Study: NCT04421456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring
Study: NCT02727998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
Study: NCT02545244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12% Chlorhexidine Mouthwash.
Description: 5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
Study: NCT04522986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: 1\*10\^8 cells are administered once a week, total four times intravenously.
Study: NCT04450758

Intervention type: PROCEDURE
Intervention: Bridge to Surgery (stent or stoma)
Description: The study is an observational study and patients will not be randomized. Resection is defined as upfront surgical resection, Bridge to Surgery as a two stage procedure.
Study: NCT02188810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PAL
Description: Single dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PAL
Description: Single dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PAL
Description: Single dose administered intramuscularly.
Study: NCT04047472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6mg
Description: Intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2 mg
Description: Intravitreal injection
Study: NCT02188810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PAL
Description: Single dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PAL
Description: Single dose administered intramuscularly.
Study: NCT02075892

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mushroom Blend
Description: Scivation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04715971

Intervention type: DIAGNOSTIC_TEST
Intervention: portable ultrasound bladder scan
Description: A post-void residual volume was measured using a Verathon BladdersScan BVI 3000.